All types of cancer cells appear to have at least one essential thing in common: They have faulty genes. At the center of every cell in our bodies, there is a nucleus containing thousands of genes made of DNA. Genes are coded instructions for making proteins, the molecules that control how cells work.
Gene Therapy Facts
- Broad category including several experimental treatment approaches
- Involves genetically modifying cancer cells, viruses or immune cells
- Bears risk of severe side effects and complications
- Available to mesothelioma patients through clinical trials
A cell with healthy DNA will perform its function in the body, create new cells as needed and destroy itself when it is damaged beyond repair. However, when a carcinogen such as asbestos damages the DNA in a cell, it may cause the cell to grow and divide out of control, leading to cancer.
Many researchers believe that just as faulty genes are the key to cancer formation, modified genes may be the key to cancer treatment. Mesothelioma researchers are hopeful that gene therapy will bring us closer to a cure for mesothelioma.
“Gene therapy” is a broad category that refers to several emerging treatment approaches involving the novel science of genetic modification. It wasn’t until recently in 2017 that the U.S. Food and Drug Administration (FDA) approved a gene-therapy-based cancer treatment for the first time.
So far, most gene therapies tested for mesothelioma have shown either limited effectiveness or severe side effects and risks of complications. For this reason, all types of gene therapy for mesothelioma are experimental and only available through clinical trials.
Inserting Tumor-Suppressing Genes
The most obvious gene therapy approach is to fix the genetic fault that causes cells to become cancerous in the first place. To perform this medical feat, however, scientists have to overcome two major challenges.
First, researchers have not been able to pinpoint a specific gene that can stop the progression of mesothelioma in most patients. The likeliest candidates are natural “tumor-suppressing genes” that prevent genetic mutations or ensure mutant cells self-destruct before they grow into tumors. The p53 gene, the BAP1 gene and microRNA gene 16 have all been studied as genes that may be able to stop the progression of mesothelioma.
Second, inserting these tumor-suppressing genes requires a microscopic delivery vehicle, or vector, that can penetrate deep into a tumor. Genetically modified viruses and specially designed nanoparticles are both in development as gene therapy vectors.
Connect with a Mesothelioma Doctor
Finding a mesothelioma specialist is critical for improving prognosis and getting the best treatment plan.Get Help Now
Chemotherapy Guided by ‘Suicide Genes’
The same vectors that could carry tumor-suppressing genes could also insert artificial “suicide genes” into cancer cells.
If researchers can develop a vector that infects all the cells in a tumor while leaving the rest of the body’s cells alone, it would enable a special form of targeted chemotherapy called suicide gene therapy. The artificial suicide gene causes cancer cells to produce an enzyme that converts an otherwise harmless drug into a lethal toxin, so the drug kills cancer cells while leaving healthy cells unharmed.
Engineering Viruses to Target Cancer Cells
Rather than trying to alter cellular DNA, some researchers instead focus on modifying deadly viruses to only kill cancer cells. This approach, known as virotherapy, was discovered by accident when doctors noticed many cancer patients who contract measles experience tumor regressions. Since then, scientists have been developing modified versions of the measles virus as an experimental treatment for several types of cancer, including mesothelioma.
In a 2016 trial of virotherapy for pleural mesothelioma patients, researchers were able to safely inject a special strain of the measles vaccine directly into the cancer site, potentially fighting the cancer through viral infection as well as provoking a natural immune system response against the cancer.
Immunotherapy with Genetically Modified T-Cells
The most exciting recent development lies at the intersection of gene therapy and immunotherapy, another cutting-edge cancer treatment science. The first gene therapy for cancer approved by the FDA is known by the brand name Kymriah and generically referred to as CAR T-cell therapy. Kymriah’s makers call it a “living drug,” because it is produced by extracting the patient’s own immune cells and reprogramming them to target cancer.
CAR T-cell therapy represents one of the first truly individualized and targeted cancer treatments, but it also has significant limitations: Kymriah is FDA-approved only for leukemia, it is extremely expensive, and it comes with the risk of severe side effects. Nevertheless, this technology has the potential to improve outcomes for mesothelioma patients in the future.
6 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- American Society of Gene & Cell Therapy. (n.d.). Cancer Gene Therapy and Cell Therapy. Retrieved from: http://www.asgct.org/general-public/educational-resources/gene-therapy-and-cell-therapy-for-diseases/cancer-gene-and-cell-therapy
- Bononi, A. et al. (2017). BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Retrieved from: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature22798.html?foxtrotcallback=true
- Cancer Research UK. (2014, December 4). Gene therapy. Retrieved from: http://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/biological-therapy/types/gene-therapy
- Kao, S. et al. (2015, June 15). A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. Retrieved from: http://www.atsjournals.org/doi/abs/10.1164/rccm.201503-0461LE#.VYOOCl7DJqs
- Peikert, T. et al. (2017, January). OA13.07 Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma. Retrieved from: http://www.jto.org/article/S1556-0864(16)31546-5/fulltext
- U.S. Food and Drug Administration. (2017, August 30). FDA approval brings first gene therapy to the United States. Retrieved from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified February 4, 2020